Eli Lilly and Company: Neoplasms trials
The registry lists 73 Neoplasms studies with Eli Lilly and Company as lead sponsor. 8 are open to participants now and 42 have results posted.
Early Phase 1 1Phase 1 50Phase 2 23Phase 3 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4336619 in Adult Participants With Advanced Solid TumorsNot yet recruitingNCT07928258Phase 1
- A Study of [18F]LY4214835 in Healthy Volunteers and Participants With CancerRecruitingNCT07258836Phase 1
- A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerRecruitingNCT07169851Phase 2
- A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy ParticipantsRecruitingNCT07046559Phase 1
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 3
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingNCT05999994Phase 2
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2
- Master Rollover Protocol for Continued Safety Assessment of Study DrugAvailableNCT02632994
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
- A Study of AK-01 (LY3295668) in Solid TumorsCompletedNCT03092934Phase 1/2Results posted
- A Study of Ramucirumab (LY3009806) in Children With Refractory Solid TumorsCompletedNCT02564198Phase 1Results posted
- A Study of Olaratumab in Japanese Participants With Advanced CancerCompletedNCT02377752Phase 1Results posted
- A Study of LY3022855 In Participants With Breast or Prostate CancerCompletedNCT02265536Phase 1Results posted
- A Study of LY3164530 in Participants With CancerCompletedNCT02221882Phase 1Results posted
- A Study of LY2835219 in Participants With CancerCompletedNCT02117648Phase 1Results posted
- A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their BodyTerminatedNCT02014116Phase 1Results posted
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
- A Study of LY3039478 in Participants With Advanced CancerCompletedNCT01695005Phase 1Results posted
- A Study of IMC-TR1 in Participants With Advanced Solid TumorsCompletedNCT01646203Phase 1Results posted
- A Dose-Escalation Study in Participants With Advanced CancerCompletedNCT01524224Phase 1Results posted
- A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung CarcinomaCompletedNCT01439568Phase 2Results posted
- A Study of LY2523355 in Participants With Breast CancerCompletedNCT01416389Phase 2Results posted
- A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT01391130Phase 2Results posted
- A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic CancerCompletedNCT01373164Phase 1/2Results posted
- A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of DesipramineCompletedNCT01358968Phase 1Results posted
- A Study of IMC-CS4 in Subjects With Advanced Solid TumorsCompletedNCT01346358Phase 1Results posted
- A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid TumorsCompletedNCT01288989Phase 1Results posted
- A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal CancerCompletedNCT01246960Phase 2Results posted
- A Study of LY2584702 in Solid TumorsCompletedNCT01241461Phase 1Results posted
- A Study in Advanced CancerCompletedNCT01226485Phase 1Results posted
- A Dose-Escalation Study for Patients With Advanced CancerCompletedNCT01214642Phase 1Results posted
- A Study for Participants With Advanced CancerCompletedNCT01214629Phase 1Results posted
- A Phase 1 Study of LY2874455 in Participants With Advanced CancerCompletedNCT01212107Phase 1Results posted
- Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid TumorsCompletedNCT01199822Phase 1Results posted
- A Study of IMC-RON8 in Advanced Solid TumorsCompletedNCT01119456Phase 1Results posted
- Study of IMC-11F8 in Participants With Advanced Solid TumorsCompletedNCT01088464Phase 1Results posted
- Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval ChangesCompletedNCT01017731Phase 2Results posted
- A Study of IMC-A12 in Advanced Solid TumorsCompletedNCT01007032Phase 1Results posted
- A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian CancerCompletedNCT00913835Phase 2Results posted
- A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy BeforeCompletedNCT00870870Phase 2Results posted
- A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and BevacizumabTerminatedNCT00845039Phase 2Results posted
- A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is AvailableCompletedNCT00785538Phase 1Results posted
- Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With ChemotherapyCompletedNCT00627042Phase 2Results posted
- Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal CancerCompletedNCT00420381Phase 2Results posted
- Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With CancerCompletedNCT00415636Phase 1Results posted
- A Trial for Patients With Advanced/Recurrent Endometrial CancerCompletedNCT00377520Phase 2Results posted
- An Open Label Study of Oral Enzastaurin in Participants With CancerCompletedNCT00309140Phase 2Results posted
- Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid TumorsCompletedNCT00110357Phase 1Results posted
- Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to ChemotherapyCompletedNCT00083720Phase 2Results posted
- A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyActive, not recruitingNCT06413706Phase 2
- Early Clinical Evaluation of 18F-LY3546117 in Tumor ImagingStatus unknownNCT04721756Early Phase 1
- A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerCompletedNCT03027284Phase 1
- A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck CancerCompletedNCT02555644Phase 1
- A Study of LY3023414 in Japanese Participants With Advanced CancerCompletedNCT02536586Phase 1
- A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced CancersCompletedNCT02514603Phase 1
- A Study of Galunisertib on the Immune System in Participants With CancerCompletedNCT02304419Phase 1
- A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced CancerCompletedNCT02124148Phase 1
- Study of LY2157299 in Japanese Participants With CancerCompletedNCT01722825Phase 1
- A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent GliomasCompletedNCT01445119Phase 1
- A Study of LY2801653 in Advanced CancerCompletedNCT01285037Phase 1
- A Study of LY2624587 in Patients With Advanced CancerCompletedNCT01139788Phase 1
- Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard TherapyCompletedNCT00801177Phase 1
- Study of IMC-1121B in Patients With Tumors That Have Not Responded to TherapyCompletedNCT00793975Phase 1
- Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard TherapyCompletedNCT00786383Phase 1
- A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is AvailableCompletedNCT00785941Phase 1
- Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is AvailableCompletedNCT00768391Phase 1
- Study of Cetuximab in Combination With Tarceva in Patients With Solid TumorsCompletedNCT00207077Phase 1
- Phase II Study in Patients With Recurrent Non-Small-Cell Lung CancerCompletedNCT00063388Phase 2
- A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.CompletedNCT00035035Phase 3
- Comparing 3 Schedules of Alimta Plus GemzarCompletedNCT00034606Phase 2
- ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic CancerCompletedNCT00034463Phase 1
- Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.CompletedNCT00034125Phase 3